King H. Lam

King H. Lam

Auto-generated profile, based on publicly available information

King H. Lam

Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Cell Stem Cell
Verified
Journal Article
Open access
NLNils B. Leimkühler
Nils B. Leimkühler
HGHélène F.E. Gleitz
Hélène F.E. Gleitz
LRLi Ronghui
Li Ronghui
ISInge A.M. Snoeren
Inge A.M. Snoeren
SFStijn N.R. Fuchs
Stijn N.R. Fuchs
RSRebekka K. Schneider
Rebekka K. Schneider
Functional contributions of individual cellular components of the bone-marrow microenvironment to myelofibrosis (MF) in patients with myeloproliferative neoplasms (MPNs) are incompletely understood. We aimed to generate a comprehensive map of the stroma in MPNs/MFs on a single-cell level in murine models and patient samples. Our analysis revealed two distinct mesenchymal stromal cell (MSC) subsets as pro-fibrotic cells. MSCs were functionally reprogrammed in a stage-dependent manner with loss of their progenitor status and initiation of differentiation in the pre-fibrotic and acquisition of a pro-fibrotic and inflammatory phenotype in the fibrotic stage. The expression of the alarmin complex S100A8/S100A9 in MSC marked disease progression toward the fibrotic phase in murine models and in patient stroma and plasma. Tasquinimod, a small-molecule inhibiting S100A8/S100A9 signaling, significantly ameliorated the MPN phenotype and fibrosis in JAK2V617F-mutated murine models, highlighting that S100A8/S100A9 is an attractive therapeutic target in MPNs.

27 August 2020 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
PDF file
PKPaul G Kemps
Paul G Kemps
KHKonnie M Hebeda
Konnie M Hebeda
SPSteven T Pals
Steven T Pals
RVRobert M. Verdijk
Robert M. Verdijk
KLKing H Lam
King H Lam
AHAstrid G.S. van Halteren
Astrid G.S. van Halteren
Histiocytic disorders are a spectrum of rare diseases characterised by the accumulation of macrophage‐, dendritic cell‐, or monocyte‐differentiated cells in various tissues and organs. The discovery of recurrent genetic alterations in many of these histiocytoses has led to their recognition as clonal neoplastic diseases. Moreover, the identification of the same somatic mutation in histiocytic lesions and peripheral blood and/or bone marrow cells from histiocytosis patients has provided evidence for systemic histiocytic neoplasms to originate from haematopoietic stem/progenitor cells (HSPCs). Here, we investigated associations between histiocytic disorders and additional haematological malignancies bearing the same genetic alteration(s) using the nationwide Dutch Pathology Registry. By searching on pathologist‐assigned diagnostic terms for the various histiocytic disorders, we identified 4602 patients with a putative histopathological diagnosis of a histiocytic disorder between 1971 and 2019. Histiocytosis‐affected tissue samples of 187 patients had been analysed for genetic alterations as part of routine molecular diagnostics, including from nine patients with an additional haematological malignancy. Among these patients, we discovered three cases with different histiocytic neoplasms and additional haematological malignancies bearing identical oncogenic mutations, including one patient with concomitantKRASp.A59E mutated histiocytic sarcoma and chronic myelomonocytic leukaemia (CMML), one patient with synchronousNRASp.G12V mutated indeterminate cell histiocytosis and CMML, and one patient with subsequentNRASp.Q61R mutated Erdheim–Chester disease and acute myeloid leukaemia. These cases support the existence of a common haematopoietic cell‐of‐origin in at least a proportion of patients with a histiocytic neoplasm and additional haematological malignancy. In addition, they suggest that driver mutations in particular genes (e.g.N/KRAS) may specifically predispose to the development of an additional clonally related haematological malignancy or secondary histiocytic neoplasm. Finally, the putative existence of derailed multipotent HSPCs in these patients emphasises the importance of adequate (bone marrow) staging, molecular analysis and long‐term follow‐up of all histiocytosis patients.

1 May 2015 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
ZWZhouqiao Wu
Zhouqiao Wu
GBGeesien S. A. Boersema
Geesien S. A. Boersema
LKLeonard F. Kroese
Leonard F. Kroese
DTDiman Taha
Diman Taha
SVSandra Vennix
Sandra Vennix
JLJohan F. Lange
Johan F. Lange
Background. Anastomotic leakage after gastrointestinal surgery remains a challenging clinical problem. This study aimed to investigate the effectiveness of Tiss

9 March 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
MDMüjde Durmaz
Müjde Durmaz
OVOtto Visser
Otto Visser
EPEduardus F. M. Posthuma
Eduardus F. M. Posthuma
RBRolf E. Brouwer
Rolf E. Brouwer
DIDjamila E. Issa
Djamila E. Issa
ADAvinash G. Dinmohamed
Avinash G. Dinmohamed
It is unclear whether survival in diffuse large B-cell lymphoma (DLBCL) continues to increase in an era where rituximab-containing chemotherapy reigns for almost two decades. Therefore, we evaluated trends in primary therapy and relative survival (RS) among Dutch DLBCL patients diagnosed between 1989 and 2018. Analyses were performed separately according to the stage I (N = 6952) and stage II–IV disease (N = 20,676), stratified by calendar period and age (18–64, 65–74, and ≥75 years). The use of chemotherapy ± radiotherapy increased over time across all age and stage groups. As of the mid-2000s, >95% of chemotherapy-treated patients received chemoimmunotherapy, irrespective of age and stage. Overall, RS increased significantly over time across all age groups, especially after 2003 when rituximab-containing chemotherapy had become the standard of care. However, RS increased less pronounced between 2003–2010 and 2011–2018 than between 1989–2002 and 2003–2010. These findings were congruent across all studied stage groups. Five-year RS across the three age groups during 2011–2018 was 96%, 84%, and 67% for stage I DLBCL and 75%, 60%, and 46% for stage II–IV DLBCL. Collectively, survival in DLBCL increased modestly beyond the initial introduction of rituximab, with apparent survival differences across age and stage that warrant novel treatment approaches.

12 October 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
MDManette A. W. Dinnessen
Manette A. W. Dinnessen
MPMarjolein W. M. van der Poel
Marjolein W. M. van der Poel
STSanne H. Tonino
Sanne H. Tonino
OVOtto Visser
Otto Visser
NBNicole M. A. Blijlevens
Nicole M. A. Blijlevens
ADAvinash G. Dinmohamed
Avinash G. Dinmohamed

14 October 2014 in Surgical Infections
Verified
Journal Article
Closed access
ZWZhouqiao Wu
Zhouqiao Wu
FDFreek Daams
Freek Daams
GBGeesien S.A. Boersema
Geesien S.A. Boersema
KVKonstantinos A. Vakalopoulos
Konstantinos A. Vakalopoulos
KLKing H. Lam
King H. Lam
JLJohan F. Lange
Johan F. Lange
Background: Colorectal anastomotic leakage (CAL) is the most important complication of colorectal surgery, accounting for one third of post-operative deaths. To prevent it, many interventions have been tested in animal models, mostly rats. However, few of these models have been validated. We aimed to develop a reproducible rat CAL model by creating an anastomosis with insufficient suturing after partial colectomy. Methods: To establish the number of sutures that would create an appropriate leakage rate for research (20%–50%), partial colectomy was performed in 60 Wistar rats using a 12-suture anastomosis in the control group and an anastomosis with insufficient suturing in the experimental group, starting with five sutures. Seven days later, the rats were examined for the occurrence and severity of CAL, the presence of adhesions, and anastomotic bursting pressure. When an acceptable leakage rate was achieved, the experimental and control studies were repeated twice to confirm the adequacy of the chosen technique. Results: On day 7, five-suture and 12-suture anastomoses had leakage rates of 50% vs. 30%, 44.4% vs. 20%, and 50% vs. 20%, respectively, in the various series. Overall, the five-suture group had a significantly higher CAL rate than did the 12-suture group (48.3% vs. 23.3%; p=0.045). It also had higher CAL severity and more adhesions (p for both<0.05). The bursting pressure of these anastomoses was significantly lower than that in the 12-suture group (116.8±58.9 mm Hg vs. 150.4±50.3 mm Hg; p=0.041). Conclusion: Anastomosis with five sutures after partial colectomy provides a suitable rat CAL model. Its future applications may help to improve the consistency of CAL studies.